沛嘉医疗近日公布截至2025年6月30日止六个月的中期业绩，实现总收入3.53亿元，较去年同期增长17.3%。公司收入结构维持稳定，经导管主动脉瓣置换（TAVR）相关产品占比为45.7%，神经介入产品则贡献了54.3%，成为推动业绩增长的重要力量。数据反映出公司在结构性心脏病和神经介入领域的持续拓展能力。
Source Link沛嘉医疗近日公布截至2025年6月30日止六个月的中期业绩，实现总收入3.53亿元，较去年同期增长17.3%。公司收入结构维持稳定，经导管主动脉瓣置换（TAVR）相关产品占比为45.7%，神经介入产品则贡献了54.3%，成为推动业绩增长的重要力量。数据反映出公司在结构性心脏病和神经介入领域的持续拓展能力。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.